“A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s631. Accessed April 19, 2026. https://skin.dermsquared.com/skin/article/view/3782.